Abstract
Increased thrombin generation is frequently associated with an increase in anginal activity. A cross-over, single-blind, completely randomized study was planned in order to evaluate whether the control of thrombin generation affected the increase in anginal activity. After discharge from the hospital, 24 patients (18 men and 6 women, aged 40 to 69 years) suffering from spontaneous angina were followed up to 12 months and were alternatively treated during two consecutive 6-month periods with calcium heparin, 12,500 IU by the subcutaneous route, or with placebo by the intramuscular route, in addition to the usual antianginal medications. Thrombin generation and clinical activity of angina were assessed every 15 days by measuring fibrinopeptide A (FPA) plasma levels and by grading in three classes (symptomiess, mildly symptomatic, and severely symptomatic) the anginal activity on the basis of the number and the time concentration of the ischemic attacks and ECG changes. Low-dose heparin treatment significantly reduced both the FPA plasma level (from 4.1 ± 3.7 to 2.3 ± 1.8 ng/ml, p <0.001) and the clinical activity of angina. During heparin treatment, the frequency of the observations in the severely and mildly symptomatic classes decreased, respectively, by 53% and by 30%, whereas that in the symptomless class increased by 23% (p <0.001) in comparison with the period on placebo. Present results indicate that the control of thrombin generation obtained by low-dose heparin treatment favorably affects the degree of anginal activity in patients with spontaneous angina.
| Original language | English |
|---|---|
| Pages (from-to) | 60-67 |
| Number of pages | 8 |
| Journal | American Heart Journal |
| Volume | 115 |
| Issue number | 1 PART 1 |
| DOIs | |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin : A controlled cross-over randomized study. / Neri Serneri, Gian Gastone; Abbate, Rosanna; Prisco, Domenico; Carnovali, Marino; Fazi, Antonio; Casolo, Gian Carlo; Bonechi, Francesco; Rogasi, Pier Giorgio; Gensini, Gian Franco.
In: American Heart Journal, Vol. 115, No. 1 PART 1, 1988, p. 60-67.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Decrease in frequency of anginal episodes by control of thrombin generation with low-dose heparin
T2 - A controlled cross-over randomized study
AU - Neri Serneri, Gian Gastone
AU - Abbate, Rosanna
AU - Prisco, Domenico
AU - Carnovali, Marino
AU - Fazi, Antonio
AU - Casolo, Gian Carlo
AU - Bonechi, Francesco
AU - Rogasi, Pier Giorgio
AU - Gensini, Gian Franco
PY - 1988
Y1 - 1988
N2 - Increased thrombin generation is frequently associated with an increase in anginal activity. A cross-over, single-blind, completely randomized study was planned in order to evaluate whether the control of thrombin generation affected the increase in anginal activity. After discharge from the hospital, 24 patients (18 men and 6 women, aged 40 to 69 years) suffering from spontaneous angina were followed up to 12 months and were alternatively treated during two consecutive 6-month periods with calcium heparin, 12,500 IU by the subcutaneous route, or with placebo by the intramuscular route, in addition to the usual antianginal medications. Thrombin generation and clinical activity of angina were assessed every 15 days by measuring fibrinopeptide A (FPA) plasma levels and by grading in three classes (symptomiess, mildly symptomatic, and severely symptomatic) the anginal activity on the basis of the number and the time concentration of the ischemic attacks and ECG changes. Low-dose heparin treatment significantly reduced both the FPA plasma level (from 4.1 ± 3.7 to 2.3 ± 1.8 ng/ml, p <0.001) and the clinical activity of angina. During heparin treatment, the frequency of the observations in the severely and mildly symptomatic classes decreased, respectively, by 53% and by 30%, whereas that in the symptomless class increased by 23% (p <0.001) in comparison with the period on placebo. Present results indicate that the control of thrombin generation obtained by low-dose heparin treatment favorably affects the degree of anginal activity in patients with spontaneous angina.
AB - Increased thrombin generation is frequently associated with an increase in anginal activity. A cross-over, single-blind, completely randomized study was planned in order to evaluate whether the control of thrombin generation affected the increase in anginal activity. After discharge from the hospital, 24 patients (18 men and 6 women, aged 40 to 69 years) suffering from spontaneous angina were followed up to 12 months and were alternatively treated during two consecutive 6-month periods with calcium heparin, 12,500 IU by the subcutaneous route, or with placebo by the intramuscular route, in addition to the usual antianginal medications. Thrombin generation and clinical activity of angina were assessed every 15 days by measuring fibrinopeptide A (FPA) plasma levels and by grading in three classes (symptomiess, mildly symptomatic, and severely symptomatic) the anginal activity on the basis of the number and the time concentration of the ischemic attacks and ECG changes. Low-dose heparin treatment significantly reduced both the FPA plasma level (from 4.1 ± 3.7 to 2.3 ± 1.8 ng/ml, p <0.001) and the clinical activity of angina. During heparin treatment, the frequency of the observations in the severely and mildly symptomatic classes decreased, respectively, by 53% and by 30%, whereas that in the symptomless class increased by 23% (p <0.001) in comparison with the period on placebo. Present results indicate that the control of thrombin generation obtained by low-dose heparin treatment favorably affects the degree of anginal activity in patients with spontaneous angina.
UR - http://www.scopus.com/inward/record.url?scp=0023833745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023833745&partnerID=8YFLogxK
U2 - 10.1016/0002-8703(88)90518-2
DO - 10.1016/0002-8703(88)90518-2
M3 - Article
C2 - 3276111
AN - SCOPUS:0023833745
VL - 115
SP - 60
EP - 67
JO - American Heart Journal
JF - American Heart Journal
SN - 0002-8703
IS - 1 PART 1
ER -